



# Case 1 Autoimmune Liver Diseases

Stela Celaj, MD, PhD

# Case 1

- A 27-year-old male presents with worsening fatigue and jaundice.
- Two weeks prior to presentation, he noticed yellowing of his skin and eyes, and dark urine.
- Denies dietary supplements or new medications, no travel or sick contacts.

# Case 1

- A 27-year-old male presents with worsening fatigue and jaundice.
- Two weeks prior to presentation, he noticed yellowing of his skin and eyes, and dark urine.
- Denies dietary supplements or new medications, no travel or sick contacts.
- Graduate student, alcohol 2 drinks/week, no drugs, no tobacco

# Case 1

- A 27-year-old male presents with worsening fatigue and jaundice.
- Two weeks prior to presentation, he noticed yellowing of his skin and eyes, and dark urine.
- Denies dietary supplements or new medications, no travel or sick contacts.
- Graduate student, alcohol 2 drinks/week, no drugs, no tobacco
  
- PMHx: Ulcerative colitis, asthma
  - Pan-UC diagnosed at age 22
  - On mesalamine, well controlled symptoms
  - Last colonoscopy 8 months prior to presentation (Mayo score 4; mild disease)

# Workup

- **Labs:**

- Total bilirubin 5.3, ALT 83, AST 154, ALP 630

# Workup

- **Labs:**


- Total bilirubin 5.3, ALT 83, AST 154, ALP 630
- Hepatitis A/B/C, HIV serologies negative
- COVID PCR negative

# Workup

- **Labs:**


- Total bilirubin 5.3, ALT 83, AST 154, ALP 630
- Hepatitis A/B/C, HIV serologies negative
- COVID PCR negative
- ANA 1:80, ASMA/AMA/LK-M1 negative
- IGG4 20.4, CEA 3, CA19-9 64.2 (mildly elevated)

# MRI/MRCP





# MRI/MRCP



ERCP sphincterotomy, balloon dilatation of dominant stricture, and temporary biliary stent

Total bilirubin 5.3→3.3, ALT 83→50, AST 154→57, ALP 630→410

CBD brushings: cytology negative/Next generation sequencing (Biliseq negative)

# Follow up

- After ERCP, started on ursodiol (UDCA) at 15mg/kg/day
- Continues to feel fatigue, however jaundice and pruritus significantly improved

# Follow up

- After ERCP, started on ursodiol (UDCA) at 15mg/kg/day
- Continues to feel fatigue, however jaundice and pruritus significantly improved
- 6-months after UDCA initiation:
  - Tbili 3.3 → 2.1
  - ALT 50 → 44
  - AST 57 → 28
  - ALP 410 → 258
  - INR 1.4 → 1.1
- 12-months after UDCA initiation: there is no significant change in symptoms or labs

# Questions

- Should this patient be continued on long-term UDCA?

# Questions

- Should this patient be continued on long-term UDCA?
- Is there a role for vancomycin in the management of this patient and if yes, at what dose?

# Questions

- Should this patient be continued on long-term UDCA?
- Is there a role for vancomycin in the management of this patient and if yes, at what dose?
- What is the best strategy for cholangiocarcinoma surveillance in this patient with a dominant stricture?

# Questions

- Should this patient be continued on long-term UDCA?
- Is there a role for vancomycin in the management of this patient and if yes, at what dose?
- What is the best strategy for cholangiocarcinoma surveillance in this patient with a dominant stricture?
- Should the diagnosis of PSC change management of his UC (e.g. continue mesalamine vs switch to azathioprine vs newer biologics)?

# Question 1





# Question 1

Where was ursodiol originally identified and extracted from?



# Question 1

- It was first identified and extracted from the bile of bears of genus *Ursus* from which its name derived.



# Question 2

- What is the capital of Canada?



# Question 2

**OTTAWA!**



**Thank you!**